RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation

Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-12, Vol.90 (3), p.477-483
Hauptverfasser:	Yoshida, Tatsuya, Yoh, Kiyotaka, Niho, Seiji, Umemura, Shigeki, Matsumoto, Shingo, Ohmatsu, Hironobu, Ohe, Yuichiro, Goto, Koichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Disease Progression EGFR tyrosine kinase inhibitors Epidermal growth factor receptor mutation Exons Female Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Middle Aged Mutation Neoplasm Staging Non-small cell lung cancer Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Response Evaluation Criteria in Solid Tumors Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated with clinical outcome after treatment failure.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2015.09.025